Latest Coagulation Stories
Zoll, Kranz & Borgess, LLC, (ZKB), an experienced pharmaceutical and medical device litigation firm, is currently investigating claims of individuals who developed bleeding, clotting or other
SOUTH SAN FRANCISCO, Calif., July 16, 2014 /PRNewswire/ -- Rigel Pharmaceuticals, Inc.
First Recombinant Treatment Approved in US for Patients With GT With Refractoriness to Platelet Transfusions, With or Without Antibodies to Platelets PLAINSBORO, N.J., July 7, 2014 /PRNewswire/
LONDON, June 11, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
Transparency Market Research added a new report "Hemophilia Treatment Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019" to its report store.
Seven-fold lower incidence of VTEs in patients treated with ISIS-FXIRx compared to enoxaparin CARLSBAD, Calif., May 22, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc.
- Kogenate® FS antihemophilic factor (recombinant) approved for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults with hemophilia A WHIPPANY,
Data showing improved pharmacokinetic profile to be presented at World Federation of Hemophilia Congress MELBOURNE, Australia, May 11, 2014 /PRNewswire/ -- Interim Phase II/III and
LONDON, May 5, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
KING OF PRUSSIA, Pa., May 2, 2014 /PRNewswire/ -- CSL Behring today announced that the first patient has been enrolled
- The governor of a province or people.